GammaTile by GT Medical Technologies, Inc.

GammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors.

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

The GammaTile team is pleased to announce the interim results of the Phase 3 Randomized Controlled Trial, which were recently presented at the 2025 Congress of Neurological Surgeons Annual Meeting.

The study found that GammaTile reduced the risk of tumor recurrence or death by more than 50% compared to standard of care (surgery followed by delayed stereotactic radiation). Importantly, these gains were achieved without any increase in treatment-related side effects, reinforcing the safety and efficacy of immediate, targeted radiation delivered at surgery.(1)

The findings represent a significant step forward in brain metastasis care and highlight the growing impact of GammaTile in improving patient outcomes. Together, we’re changing what’s possible for patients with brain tumors, delivering immediate radiation when and where it is needed most.

Read the press release to learn more: https://t.co/ToCMmtrPKo

This interim analysis is based on data from 168 of the 230 patients enrolled in the study. Randomization was conducted on a 1:1 basis. All results presented are preliminary and subject to change as additional data become available from the remaining enrolled participants.

REFERENCE: Weinberg J, Beckham TH, Lin H, et al. Interim analysis of a phase 3 randomized controlled trial for treatment of newly diagnosed metastatic brain tumors(ROADS, NCT04365374).

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

#ABSBrachy26 kicks off this month! Join the GammaTile team for an evening of conversation and connection as we reflect on the recent Full Analysis of the Phase 3 ROADS Trial data presented as a Late-Breaking Abstract on May 30, 2026 at the ASCO Annual Meeting, celebrating progress, partnership, and what's next in the future of brain tumor care.

Reserve your spot: https://t.co/17Os0cJsQY

See full prescribing information at https://t.co/44JKFQqlRT

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

Learn more about GammaTile at #ABSBrachy26! Stop by our booth and join our Friday evening reception to hear about our Phase 3 Full 230 Patient Analysis of the ROADS Trial for Newly Diagnosed Brain Metastases.

Reserve your spot: https://t.co/HhOmr7Y3Jt

See full prescribing information at https://t.co/Obnnfk0iVE

[The Wall Street Journal @WSJ]

A postage stamp-sized implant eliminates a dangerous waiting period that has long worsened outcomes for cancer patients. https://t.co/KSn4ZfxF4p

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

NEW DATA
New randomized, multicenter ROADS Trial Phase 3 Results — presented today in a late-breaking abstract at the 2026 ASCO Annual Meeting — demonstrate that surgery with GammaTile significantly improves upon the current standard of care in patients with newly diagnosed brain metastases.

The study demonstrated that GammaTile cesium-131 collagen tile-based radiation therapy (TBRT), implanted directly into the tumor site during surgery, resulted in dramatically lower rates of tumor regrowth, a superior likelihood of living longer without recurrence, and significantly improved overall survival compared to standard stereotactic radiation therapy (SRT).

These findings highlight the value of immediate, targeted radiation therapy and collaborative clinical research in advancing care for patients with newly diagnosed operable brain metastases.

Read the abstract: https://t.co/17WXkyb0hr

Reference: Weinberg J. J Clin Oncol 44, 2026 (suppl 17; abstr LBA2000)

See full prescribing information at https://t.co/WL6dFCC57V

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

Join us today at 3 PM CDT at ASCO 2026 for “Final results of a randomized, controlled, phase 3 trial comparing resection and post-operative stereotactic radiation versus resection and cesium-131 tile-based radiation for treatment of newly diagnosed brain metastases.”

Learn more: https://t.co/FD64EX78bX

Not attending ASCO? Sign up to see the data once released: https://t.co/8k8MK9lQuR

See full prescribing information at https://t.co/MkXvSHQwsB

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

“Final results of a randomized, controlled, phase 3 trial comparing resection and post-operative stereotactic radiation versus resection and cesium-131 tile-based radiation for treatment of newly diagnosed brain metastases” is being presented tomorrow at ASCO 2026! Hear the Phase 3 Results for the ROADS Trial at 3PM CDT.

Learn more: https://t.co/du7Pj8NIW3

Not attending ASCO? Sign up to see the data once released: https://t.co/AHqtD4s4vv

See full prescribing information at https://t.co/YUnFcE4BIs

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

Brain Tumor Awareness Month may be coming to a close, but awareness is just the beginning.

At GammaTile, our commitment to the brain tumor community is built into everything we do. We remain focused on what matters most: supporting patients on their treatment journey and advancing brain tumor care.

#BrainTumorAwarenessMonth #BTAM #GammaTile

See full safety information at https://t.co/SSXUM2cT6t

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

In this prospective, multi-center observational study demonstrates that resection and GammaTile for aggressive, recurrent meningiomas resulted in encouraging local control and low adverse event rate.

Specifically, the study found that for all Grades combined, local control at 6, 12, and 15 months were 94.4%, 78.3%, and 67.0%. These findings represent a meaningful step forward and a promising approach in the treatment of recurrent meningioma.

Read the abstract: https://t.co/bhQSHyHtUI

#BrainTumorAwarenessMonth #BTAM #GammaTile #RecurrentMeningioma

REFERENCE: Desai B, et al. Neuro-Oncology. 2025;27(Suppl 5):v107.

See full prescribing information at https://t.co/nkIGwbOfd2

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

Treatment is challenging for recurrent meningioma, especially for previously irradiated tumors. Neurosurgeon Joseph Zabramski, MD, shares his perspective on where GammaTile belongs in the treatment discussion.

Dr. Zabramski is a research investigator in the Barrow Aneurysm and AVM Research Center at Barrow Neurological Institute.

#BrainTumorAwarenessMonth #BTAM #GammaTile #RecurrentMeningioma

Quotes are based on the personal experience and learnings of the featured healthcare professionals.

See full prescribing information at https://t.co/LFP8mwVfq7

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

Mark your calendars for the American Society of Clinical Oncology Annual Meeting! Hear the oral abstract session on GESTALT Clinical Trial Outcomes on Sunday, May 31st, followed by a session on the BRIDGES Clinical Trial on Monday, June 1st.

Learn more about the GESTALT session: https://t.co/jkb5CGGUjb
Learn more about the BRIDGES session: https://t.co/0xxJjb5QEg

See full prescribing information at https://t.co/CEgAA5B755

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

Brain Tumor Awareness Month wraps up this week, but not before a final clinical spotlight on recurrent meningioma.

This prospective, multi-center observational study demonstrates that resection and GammaTile for aggressive, recurrent meningiomas resulted in encouraging local control and low adverse event rate.

Check back in tomorrow to hear from neurosurgeon Joseph Zabramski, MD, about how GammaTile fits into the treatment plan for recurrent meningioma.

Read the abstract: https://t.co/RX0W8FKUqY

#BrainTumorAwarenessMonth #BTAM #GammaTile #RecurrentMeningioma

REFERENCE: Desai B, et al. Neuro-Oncology. 2025;27(Suppl 5):v107.

See full prescribing information at https://t.co/hNCp8s2snf

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

ASCO 2026 is right around the corner! Join the GammaTile team this Saturday for “Results of a randomized, controlled, phase 3 trial comparing resection and post-operative stereotactic radiation versus resection and cesium-131 tile-based radiation for treatment of newly diagnosed brain metastases.”

Learn more: https://t.co/GM3O6R7DcY

Not attending ASCO? Sign up to see the data once released: https://t.co/2S5ktHtmEe

See full prescribing information at https://t.co/Dc2eLPgntR

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

Learn more about BRIDGES, our phase 3 randomized trial of immediate postoperative cesium-131 tile-based radiation therapy followed by abbreviated chemoradiation for newly diagnosed glioblastoma, at the American Society of Clinical Oncology Annual Meeting.

View the poster from 1:30-4:30 CDT in Hall A on Monday, June 1st. We hope to see you there!

Learn more: https://t.co/oIZWCWQv8Q

See full prescribing information at https://t.co/iq4F92rtKS

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

Join the GammaTile team for a presentation at the American Society of Clinical Oncology titled “Outcomes of a feasibility and safety trial of tile-based radiation therapy with cesium-131 followed by external beam radiation therapy with concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma.”

Learn more: https://t.co/RgzTL6lx6e

See full prescribing information at https://t.co/m9lR7VDGBX

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

In a prospective, multi-institutional study examining the efficacy of GammaTile for the treatment of recurrent brain metastases, cumulative incidences of local failure per-patient at 6, 12, and 15 months were 11.7%, 18.4%, and 22.5%, respectively.

This analysis demonstrates encouraging outcomes with GammaTile for salvaging previously irradiated, recurrent brain metastases after prior radiotherapy.

Read the abstract: https://t.co/QKQuQopAQS?

#RecurrentBrainMetastases #BrainMets #GammaTile

REFERENCE: Kotecha R, et al. Neuro-Oncology. 2025;27(Suppl 5):v104.

See full prescribing information at https://t.co/IJnUu38eS7

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

Join us at the American Society of Clinical Oncology Annual Meeting on Saturday, May 30th, to hear the “Final results of a randomized, controlled, phase 3 trial comparing resection and post-operative stereotactic radiation versus resection and cesium-131 tile-based radiation for treatment of newly diagnosed brain metastases.”

Learn more: https://t.co/zUTEhVUk7x

Not attending ASCO? Sign up to see the data once released: https://t.co/TG52aggMyq

See full prescribing information at https://t.co/fLiW36xLmo

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

“The ability to deliver immediate, localized radiation therapy at the time of surgery helps to avoid delays, reduces reliance on post-operative radiosurgery, and mitigates the overall cumulative toxicity,” says Radiation Oncologist Rupesh Kotecha, MD.

In this prospective, multi-institutional study, Dr. Kotecha examined the efficacy of GammaTile for the management of patients with recurrent brain metastases. The analysis demonstrated encouraging outcomes with GammaTile for treating previously irradiated, recurrent brain metastases.

Read the abstract: https://t.co/QqdTHK5RRF?

Dr. Kotecha is the Chief of Radiosurgery in the Department of Radiation Oncology and Director of the Central Nervous System Metastasis program at Miami Cancer Institute.

#RecurrentBrainMetastases #BrainMets #GammaTile #BrainTumorAwarenessMonth

Quotes are based on the personal experience and learnings of the featured healthcare professionals.

REFERENCE: Kotecha R, et al. Neuro-Oncology. 2025;27(Suppl 5):v104.

See full prescribing information at https://t.co/jGlqoShIzn

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

We’re halfway through Brain Tumor Awareness Month and this week’s focus is on clinical data supporting GammaTile’s use in the treatment of recurrent brain metastases.

This prospective, multi-institutional study showed encouraging outcomes with GammaTile for salvaging previously irradiated, recurrent brain metastases after prior radiotherapy across 19 different centers with a low cumulative incidence rate of local failure and adverse radiation effects.

Tune in tomorrow to hear from one of the study’s authors, Dr. Rupesh Kotecha.

Read the abstract: https://t.co/IdEmBFA8X3?

#RecurrentBrainMetastases #BrainMets #GammaTile #BrainTumorAwarenessMonth

REFERENCE: Kotecha R, et al. Neuro-Oncology. 2025;27(Suppl 5):v104.

See full prescribing information at https://t.co/Hy6DZ73Mve